Search clinical trials for: UB-621

Total 1175 results

UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

Recurrent Genital Herpes
United BioPharma
Taipei Veterans General Hospital, Taiwan

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

Herpes Simplex Virus Infection

Taiwan
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

Recurrent Genital Herpes
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

Chronic Spontaneous Urticaria
United BioPharma

Not yet recruiting

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

Genital Herpes
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients (HIV-1)

HIV-1-infection
United BioPharma
National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho... and other collaborators

Completed

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

HIV-1 Infection

Taiwan
United Biomedical Inc., Asia
Vaxxinity, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

COVID-19

Taiwan
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

HIV-1-infection
United BioPharma

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Urticaria Chronic

Taiwan
Vaxxinity, Inc.
Diagnósticos da América S/A (DASA)

Withdrawn

A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

Covid-19 | SARS-CoV-2 | Coronavirus
United Biomedical Inc., Asia
Vaxxinity, Inc.

Terminated

A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers

COVID-19

Taiwan
United BioPharma
Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Veterans... and other collaborators

Completed

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

HIV-1 Infection

Taiwan
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
United Biomedical
Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital. and other collaborators

Completed

Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults

HIV-1 Infection in Adults

Taiwan
United Biomedical

Completed

Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults

HIV-1 Infection in Adults (Asymptomatic)

Taiwan
United Biomedical Inc., Asia

Withdrawn

A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.

COVID-19
United Biomedical Inc., Asia
Vaxxinity, Inc.

Completed

A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

COVID-19

Taiwan
United BioPharma
Tri-Service General Hospital

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

Breast Neoplasm

Taiwan
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
National Institute of Allergy and Infectious Diseases...

Recruiting

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Multi-Drug Resistant Hiv-1 Infection | HIV-1 Infection

United States
United BioPharma

Recruiting

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Taiwan
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
United BioPharma
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Completed

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

HIV-1 Infection

Taiwan
Vaxxinity, Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants

Migraine

Belgium
United BioPharma

Not yet recruiting

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

HIV-1 Infection
Medical University of South Carolina
Augusta University

Completed

Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment (FEAST)

Depression

United States
United BioPharma

Not yet recruiting

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

HIV-1 Infection
United BioPharma

Withdrawn

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

HIV-1 Infection
AstraZeneca

Completed

Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge

LPS Challenge, Neutrophils

United Kingdom
United BioPharma

Withdrawn

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

HIV-1 Infection

China
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Germany, United Kingdom, Australia, France, Netherlands, Sweden, Switzerland
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Vaxxinity, Inc.
Syneos Health; Coalition for Epidemic Preparedness Innovations

Active, not recruiting

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

COVID-19 Vaccines

Philippines, United States, Panama
Vertex Pharmaceuticals Incorporated

Completed

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Cystic Fibrosis

United States
NYU Langone Health

Recruiting

UB-312 in Patients With Synucleinopathies

Parkinson Disease | Multiple System Atrophy

United States
United Biomedical
National Taiwan University Hospital; Taipei Veterans General Hospital, Taiwan

Completed

Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease

Alzheimer's Disease

Taiwan
United Neuroscience Ltd.

Terminated

An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311

Alzheimer's Disease

Taiwan
United Neuroscience Ltd.
Worldwide Clinical Trials; Centre for Human Drug Research, Netherlands; Vaxxinity...

Completed

Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

Parkinson's Disease | Parkinsonism

Netherlands
United Neuroscience Ltd.

Completed

Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients

Alzheimer's Disease

Taiwan
Hospices Civils de Lyon

Completed

Validation of the 3D-CAM and the UB-CAM in French (French-UB-CAM)

Delirium

France
Vertex Pharmaceuticals Incorporated

Completed

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
UBI Pharma Inc.

Completed

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

Renal Anemia
Centro Universitario La Salle

Unknown

Breathing Protocol in Breath-hold Divers

Apnea | Exercise Training | Breathing Exercises | Breathholding

Spain
Vertex Pharmaceuticals Incorporated

Completed

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Juul Labs, Inc.

Completed

Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS

Tobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, Electronic

United States
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

Mucociliary Clearance

United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

United States

3

Subscribe